Prospective Grant of Exclusive License: Treatment of Dopaminergic Neurodegenerative Disorders

الملخص

This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Applications SN 07/401,141 and 07/892,485, both entitled ``A Method for the Treatment of Dopaminergic Neurodegenerative Disorders'' to Phoenix: Regenerative Technologies, Inc. of Peoria, Illinois. The patent rights in this invention have been assigned to the United States of America. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The patent applications disclose a novel surgical implantation method, which comprises implantation, into the brain, of suitable histocompatible leukocytes activates by such agents as plant mitogens, lymphokines, a